ENVALITH
東邦ホールディングス株式会社 logo

TOHO HOLDINGS CO.,LTD.

8129・Prime Market・Wholesale Trade

Official website
東邦ホールディングス株式会社 logo
TOHO HOLDINGS CO.,LTD.8129

Business

Toho Holdings is a holding company originating from a pharmaceutical wholesale business founded in 1948, comprising 43 subsidiaries and 17 affiliated companies. Its core Pharmaceutical Wholesale Business (Toho Yakuhin and others) accounts for approximately 93% of net sales, supplying pharmaceuticals and healthcare-related products to hospitals, clinics, and dispensing pharmacies. In addition, the company operates the Dispensing Pharmacy Business (net sales of ¥100,538 million), which runs Insurance Dispensing Pharmacies; the Pharmaceutical Manufacturing & Sales Business (Kyoso Mirai Pharma), which handles Generic Drugs manufacturing and Contract Manufacturing of Injectable Drugs (CDMO); and businesses in healthcare ICT and other healthcare-related peripheral fields. Under the group slogan "For All Who Wish for Good Health," the company aims to transform itself into a comprehensive healthcare total solutions provider.

Business Model

The majority of revenue arises from trading margins in the Pharmaceutical Wholesale Business (net sales of ¥1,494,868 million against a cost of sales of ¥1,400,976 million). Profit margins are managed through price negotiations based on the drug pricing standard and through visualization and optimization of distribution costs. In the Dispensing Pharmacy Business, revenue is derived from insurance dispensing fees, while the Pharmaceutical Manufacturing & Sales Business earns fees from Generic Drugs sales and contract manufacturing. The company is diversifying value-added revenue by expanding customer support businesses, such as the medical appointment system "LXMATE HeLios cloud" and the picking audit system "EveryPick (Cloud-based Picking Audit System)".

Company Strengths

The company operates a nationwide wholesale network through consolidated subsidiaries including Toho Yakuhin, Kyushu Toho, Seieru, and Koyo. Sales are driven by exclusive wholesale-limited products such as anticancer drugs, specialty pharmaceuticals, diabetes treatment drugs, and shingles vaccines. Pharmaceutical Wholesale Business revenue for FY2026 (ending March 2026) reached ¥1,494,868 million (up 2.1% year on year).

The company completed the reorganization of dispensing pharmacy business subsidiaries under the Pharma Cluster, consolidating from 24 companies as of end-March 2024 to 4 companies as of April 1, 2026. Despite upfront reorganization costs, segment profit for FY2026 (ending March 2026) improved significantly to ¥1,397 million (up 64.0% year on year), with labor-saving effects from the establishment of the Prescription Input Center beginning to materialize.

The company is constructing the full-line service framework for specialty products requiring high-value, strict management, through initiatives including the start of construction on the integrated logistics center "TBC Tokai" (scheduled to begin operations in FY2027), development of the Haneda Packaging Center (Secondary Pharmaceutical Packaging Facility) (scheduled to begin accepting contract work within FY2026), launch of the Specialty Product Home Delivery Service "L1MON," and investments in Ishin Pharma, Serve, and Biopharma.

ENVALITH's Perspective

In FY2026 (ending March 2026), revenue increased 2.3% year-on-year to ¥1,553,364 million, securing revenue growth; however, operating profit fell 12.3% year-on-year to ¥16,601 million and ordinary profit fell 19.7% year-on-year to ¥16,631 million, marking a second consecutive period of profit decline. As external factors, the April 2025 mid-year drug price revision (covering 53% of all items) and rising pharmaceutical procurement costs directly hit profits. The gross profit margin declined slightly to 7.9% from 8.0% in the previous period, highlighting the limits of the company's pricing pass-through capability as an emerging issue.

The earnings forecast for FY2027 (ending March 2026) is revenue of ¥1,601,000 million (up 3.1% year-on-year) and operating profit of ¥14,800 million (down 10.9% year-on-year), anticipating a third consecutive period of operating profit decline. The main causes are the continued decline in drug prices following the April 2026 drug price revision and rising procurement costs. In addition, equity-method investment losses in FY2026 (ending March 2026) expanded sharply to ¥1,936 million (from ¥189 million in the previous period), and close attention is warranted regarding the performance trends of affiliated companies as a downside risk to ordinary profit.

Under the Medium-Term Management Plan 2026-2028 "Jidai wo Kakeru," with FY2029 (ending March 2029) as the final year, the company sets forth a transformation into a Healthcare Total Solution Provider, with strengthening the profitability of the Pharmaceutical Wholesale Business and the early expansion of new businesses as twin pillars. While growth investments such as the establishment of the CVC fund "TOHO Ventures" and investments in startups are moving into full swing, short-term profit contributions remain limited. The effectiveness of governance enhancements (establishment of a CGO position and a Compliance Promotion Department) and the path toward improving ROE will be key to the mid-to-long-term evaluation.

Growth Strategy

Transformation into a comprehensive healthcare provider centered on three pillars: strengthening specialty capabilities, logistics reform, and new business creation

Commenced construction of "TBC Tokai," an integrated logistics center combining a manufacturer logistics warehouse and a wholesale logistics warehouse. Scheduled to begin operations in FY2027. Aims to strengthen the profitability of the Pharmaceutical Wholesale Business through visualization and optimization of distribution costs and improved delivery efficiency.

Preparations are underway to begin contract operations within FY2026 at the "Haneda Packaging Center," a secondary packaging facility for prescription drugs established within the same facility as TBC Dyna Base. This will accelerate the establishment of a full-line specialty product service.

The number of dispensing pharmacy business subsidiaries under Pharma Cluster, which stood at 24 companies as of the end of March 2024, has been consolidated to 4 companies as of April 1, 2026. Labor savings were also achieved through the establishment of the Prescription Input Center. Segment profit for FY2026 (ending March 2026) improved significantly to ¥1,397 million (up 64.0% year on year).

Promoting investment in advanced overseas startups, primarily in the fields of drug discovery/biotechnology and healthcare DX. In April 2026, made an investment in Metaphore Biotechnologies Inc. This is a core initiative of the growth investment acceleration phase under the Medium-Term Management Plan 2026-2028.

Formulated a new medium-term management plan with FY2029 (ending March 2029) as the final year. Aiming to transform into a Healthcare Total Solution Provider through the twin pillars of strengthening the profitability of the Pharmaceutical Wholesale Business and the early expansion of new businesses. Plans for FY2027 (ending March 2027) call for net sales of ¥1,601,000 million and operating profit of ¥14,800 million.

Last updated: July 19, 2026